

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number  
WO 2005/026208 A2

(51) International Patent Classification<sup>7</sup>: C07K 14/705,  
G01N 33/94, C12N 5/10, C07D 471/00, 513/00

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/EP2004/052029

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:  
3 September 2004 (03.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PCT/EP03/10263  
12 September 2003 (12.09.2003) EP

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,  
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

(71) Applicant (for all designated States except US):  
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-  
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SMANS, Karine,  
Alfonsine, Astrid [BE/BE]; Janssen Pharmaceutica N.V.,  
Turnhoutseweg 30, B-2340 Beerse (BE). GLJSEN, Hen-  
ricus, Jacobus, Maria [NL/NL]; Janssen Pharmaceutica  
N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: JANSSEN PHARMACEU-  
TICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

Published:

- without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

(54) Title: CHIMERIC GABAB RECEPTOR

(57) Abstract: The present invention provides an isolated GABA<sub>B</sub> receptor protein comprising at least one GABA<sub>B</sub>R1 a subunit and at least one GABA<sub>B</sub>R2a subunit, characterized in that said GABA<sub>B</sub> receptor has one high affinity agonist binding site and one low affinity agonist binding site. In particular the isolated recombinant GABA<sub>B</sub> receptor protein expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB. It is thus an object of the present invention to provide the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB. 20 The invention also provides the use of the aforementioned cell line in a method to identify GABA<sub>B</sub> receptor agonists using a functional or a binding assay. In particular in a radioligand-binding assay comprising the use of radiolabeled agonists such as for example <sup>3</sup>H-GABA or <sup>3</sup>H-baclofen. In a particular embodiment the present invention provides the use of the aforementioned GABA<sub>B</sub> receptor in a method to identify a high affinity GABA<sub>B</sub> receptor agonist using a functional or a binding assay. In particular in a radioligand-binding assay comprising the use of radiolabeled agonists such as for example <sup>3</sup>H-GABA or <sup>3</sup>H-baclofen. Alternatively, the aforementioned binding assays are performed on cellular extracts, in particular cellular membrane preparations of the aforementioned cells.

WO 2005/026208 A2

## CHIMERIC GABA<sub>B</sub> RECEPTOR

The present invention provides a novel method to identify substances that are agonists of GABA<sub>B</sub> receptors, using a <sup>3</sup>H-GABA binding assay in recombinant GABA<sub>B</sub>R1a/R2 receptor expressing cells.

### BACKGROUND OF THE INVENTION

GABA (γ-amino-butyric acid) is the most widely distributed amino acid inhibitory neurotransmitter in the central nervous system (CNS) activating two distinct families of receptors; the ionotropic GABA<sub>A</sub> and GABA<sub>C</sub> receptors for fast synaptic transmissions, and the metabotropic GABA<sub>B</sub> receptors governing a slower synaptic transmission.

GABA<sub>B</sub> receptors are members of the superfamily of seven transmembrane G-protein coupled receptors that are coupled to neuronal K<sup>+</sup> or Ca<sup>2+</sup> channels. Presynaptic GABA<sub>B</sub> receptor activation has generally been reported to result in the inhibition of Ca<sup>2+</sup> conductance, leading to a decrease in the evoked release of neurotransmitters. Post-synaptically the major effect of GABA<sub>B</sub> receptor activation is to open potassium channels, to generate post-synaptic inhibitory potentials.

The expression of GABA<sub>B</sub> receptors is widely distributed in the mammalian neuronal axis, with particularly high levels in the molecular layer of the cerebellum, interpeduncular nucleus, frontal cortex, olfactory nuclei, thalamic nuclei, temporal cortex, raphe magnus and spinal cord. GABA<sub>B</sub> receptors are also present in the peripheral nervous system, both on sensory nerves and on parasympathetic nerves. Their ability to modulate these nerves give them potential as targets in disorders of the lung, GI tract and bladder (Belley et al., 1999, *Bioorg. Med. Chem.* 7:2697-2704).

A large number of pharmacological activities have been attributed to GABA<sub>B</sub> receptor activation, such as for example, analgesia, hypothermia, catatonia, hypotension, reduction of memory consolidation and retention, and stimulation of insulin, growth hormone and glucagon release (see Bowery, 1989, *Trends Pharmacol. Sci.* 10:401-407 for a review). It is well accepted that GABA<sub>B</sub> receptor agonists and antagonists are pharmacologically useful in indications such as stiff man syndrome, gastroesophageal reflux, neuropathic pain, incontinence and treatment of cough and cocaine addiction. For example, the GABA<sub>B</sub> receptor agonist baclofen has been shown to reduce transient lower esophageal sphincter relaxations (TLESR) and is accordingly useful in the treatment of reflux as most episodes of reflux occur during TLESR. However, the current GABA<sub>B</sub> receptor agonists, such as baclofen, are relatively non-

selective and show a variety of undesirable behavioural actions such as sedation and respiratory depression. It would be desirable to develop more GABA<sub>B</sub> receptor agonists with an improved selectivity and less of the aforementioned undesirable effects.

5        Current methods of drug discovery generally involve assessing the biological activity of tens or hundreds of thousands of compounds in order to identify a small number of those compounds having a desired activity against a particular target, i.e. High Throughput Screening (HTS). In a typical HTS related screen format, assays are performed in multi-well microplates, such as 96, 384 or 1536 well plates, putting  
10        certain constraints to the setup of the assay to be performed including the availability of the source materials (i.e. membrane preparations of cells expressing the recombinant GABA<sub>B</sub> receptor). HTS related screens are preferably performed at room temperature with a single measurement for each of the compounds tested in the assay, requiring short cycle times, with a reproducible and reliable output.

15        Present *in vitro* screens to identify compounds as agonists of the GABA<sub>B</sub> receptor, either rely on natural, less abundant resources such as binding assays in rat brain membranes or consist of functional screening assays, such as for example Ca<sup>2+</sup> responses, c-AMP responses and effects on Ca<sup>2+</sup> and K<sup>+</sup> channels performed in cells expressing a recombinant GABA<sub>B</sub> receptor. In some of these functional assays the  
20        GABA<sub>B</sub> receptors may be co-expressed with G-proteins, e.g. G $\alpha$ 16 or Gqi5 or the chimeric G-protein G  $\alpha$ q-z5, increasing G-protein coupling (Bräuner-Osborne & Krogsgaard-Larsen, 1999, Br. J. Pharmacol. 128:1370-1374). However, a GABA<sub>B</sub> agonist binding assay that would further reduce the HTS cycle time and the resources for biochemicals such as recombinant proteins, is currently unavailable.

25        The present invention describes the development of a Chinese Hamster Ovary (CHO) cell line co-expressing the human GABA<sub>B</sub> receptor subunits GABA<sub>B</sub>R1a and GABA<sub>B</sub>R2, which were surprisingly found to demonstrate agonist binding in radioligand binding experiments. In addition, the present inventors demonstrated that the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line has one high affinity and one low affinity  
30        agonist binding site in the recombinant expressed GABA<sub>B</sub> receptor. Hence the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line provided by the present invention not only allows compound screening, but also provides a useful tool to characterize the nature of the compound-receptor interaction.

35

### SUMMARY OF THE INVENTION

The present invention provides an isolated GABA<sub>B</sub> receptor protein comprising at least one GABA<sub>B</sub>R1a subunit and at least one GABA<sub>B</sub>R2 subunit, characterized in that said GABA<sub>B</sub> receptor has one high affinity agonist binding site and one low affinity agonist binding site. In particular the isolated recombinant GABA<sub>B</sub> receptor protein expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB. It is thus an object of the present invention to provide the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB.

The invention also provides the use of the aforementioned cell line in a method to identify GABA<sub>B</sub> receptor agonists using a functional or a binding assay. In particular in a radioligand-binding assay comprising the use of radiolabeled agonists such as for example <sup>3</sup>H-GABA or <sup>3</sup>H-baclofen.

The invention further provides a method to identify GABA<sub>B</sub> receptor agonists, comprising contacting the aforementioned cell line with a test compound and measuring the binding of said test compound to the GABA<sub>B</sub> receptor. In particular the method consists of a radioligand binding assay, comprising exposing the aforementioned cells to a labelled agonist of GABA<sub>B</sub> in the presence and absence of the test compound and measure the binding of the labelled ligand to the cells according to the invention, where if the amount of binding of the labelled ligand is less in the presence of the test compound, then the compound is a potential agonist of the GABA<sub>B</sub> receptor.

It is also an object of the present invention to provide a method to identify a high affinity GABA<sub>B</sub> receptor agonist, said method comprising contacting the aforementioned cells with the radiolabeled agonist selected from the group consisting of GABA, baclofen and 3-aminopropylphosphinic acid (3-APPA a.k.a APMPA), in the presence and absence of the test compound and measure the binding of the labelled ligand to the cells according to the invention, where if the amount of binding of the labelled ligand to the high affinity binding site is less in the presence of the test compound, then the compound is a potential high affinity agonist of the GABA<sub>B</sub> receptor.

Alternatively, the aforementioned binding assays are performed on cellular extracts, in particular cellular membrane preparations of the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated

Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB.

- 5 In another embodiment the present invention provides a method to identify a GABA<sub>B</sub> receptor agonist, said method comprising contacting the aforementioned cell line with a compound to be tested and determine whether the compound activates a GABA<sub>B</sub> receptor functional response in said cells. In particular the functional response consists of modulation of the activity of ion channels or of intracellular messengers as explained hereinafter.
- 10 This and further aspects of the present invention will be discussed in more detail hereinafter.

#### BRIEF DESCRIPTION OF THE DRAWING

- 15 Figure 1 GTPγS-binding upon stimulation of membranes by GABA expressed as the percentage of maximal GABA stimulation, in the presence and absence of the positive allosteric modulator CGP7930>

- 20 Figure 2 Displacement of <sup>3</sup>H-GABA by agonists (baclofen, GABA & APMPA) and antagonists (SCH50911 & CGP54626)

Figure 3 Reproducible agonist IC<sub>50</sub> values (n=5) independent of membrane preparations.

- 25 Figure 4 Two sided <sup>3</sup>H-GABA agonist binding curve in the presence or absence of 10 μM CGP54626 (a) or JNJ 4309747-AAD (b).

#### DETAILED DESCRIPTION

- 30 For the purposes of describing the present invention: GABA<sub>B</sub>R1a or h GABA<sub>B</sub>R1a as used herein refers to the human GABA<sub>B</sub> receptor subunit known as GABA<sub>B</sub>R1a in Kaupmann et al, 1998, Proc. Natl. Acad. Sci. USA 95:14991-14996, the amino acid sequence (SEQ ID No.:2) of which can be found at GenBank Accession no. AJ225028, as well as to its mammalian orthologs. GABA<sub>B</sub>R1a also refers to other GABA<sub>B</sub> receptor subunits that have minor changes in amino acid sequence from those described

hereinbefore, provided those other GABA<sub>B</sub> receptor subunits have substantially the same biological activity as the subunits described hereinbefore. A GABA<sub>B</sub>R1a subunit has substantially the same biological activity if it has an amino acid sequence that is at least 80% identical to, preferably at least 95% identical to, more preferably at least 97% identical to, and most preferably at least 99% identical to SEQ ID No.: 2 and has a Kd or EC50 for GABA, GABA<sub>B</sub> receptor agonists such as for example baclofen and gabapentin or GABA<sub>B</sub> receptor antagonists such as for example CGP54626A, SCH 50911, saclofen and phaclofen, that is no more than 5-fold greater than the Kd or EC50 of a native GABA<sub>B</sub> receptor for GABA or the same GABA<sub>B</sub> receptor agonist or GABA<sub>B</sub> receptor antagonist.

GABA<sub>B</sub>R2 as used herein refers to the human GABA<sub>B</sub> receptor subunit known as GABA<sub>B</sub>R2 in White et al., 1998, Nature 396:679-682, the amino acid sequence (Seq Id NO.: 4) of which can be found at GenBank accession no. AF058795 as well as to its mammalian orthologs. GABA<sub>B</sub>R2 also refers to other GABA<sub>B</sub> receptor subunits that have minor changes in amino acid sequence from those described hereinbefore, provided those other GABA<sub>B</sub> receptor subunits have substantially the same biological activity as the subunits described hereinbefore. A GABA<sub>B</sub>R2 subunit has substantially the same biological activity if it has an amino acid sequence that is at least 80% identical to, preferably at least 95% identical to, more preferably at least 97% identical to, and most preferably at least 99% identical to SEQ ID No.: 4 and has in combination with a GABA<sub>B</sub>R1 subunit a Kd or EC50 for GABA, GABA<sub>B</sub> receptor agonists such as for example baclofen and gabapentin or GABA<sub>B</sub> receptor antagonists such as for example CGP54626A, SCH 50911, saclofen and phaclofen, that is no more than 5-fold greater than the Kd or EC50 of a native GABA<sub>B</sub> receptor for GABA or the same GABA<sub>B</sub> receptor agonist or GABA<sub>B</sub> receptor antagonist.

The Kd and EC50 values of the native GABA<sub>B</sub> receptor is determined using the methods known to a person skilled in the art, in particular using competition binding studies on tissue preparations such as for example described in Cross & Horton, 1987 Eur.J.Pharmacol. 141(1): 159-162. Briefly, crude synaptic membranes are prepared by homogenisation of whole brain, centrifugation (30 000 xg, 20 min.) and extensive washing. Total binding is measured by incubation of the membranes with <sup>3</sup>H-GABA or <sup>3</sup>H-baclofen, while non-specific binding is measured in the presence of 100 μM baclofen. Upon removal of unbound ligand by filtration, filters are counted in a β-counter or a Topcount Harvester (Packard). For competition experiments the binding occurs in the presence of increasing concentration of unlabeled compound.

It is thus an object of the present invention to provide an isolated GABA<sub>B</sub> receptor protein formed by at least one GABA<sub>B</sub>R1a and at least one GABA<sub>B</sub>R2 subunit further characterized in that said isolated GABA<sub>B</sub> has both a high and a low affinity agonist binding site. In a further embodiment this isolated GABA<sub>B</sub> receptor is a functional GABA<sub>B</sub> receptor expressed by a cell, wherein said cell does not normally express the GABA<sub>B</sub> receptor. Suitable cells which are commercially available, include but are not limited to L-cells, HEK-293 cells, COS cells, CHO cells, HeLa cells and MRC cells, in particular CHO cells wherein the GABA<sub>B</sub> receptor protein comprises at least one GABA<sub>B</sub>R1a subunit encoded by the oligonucleotide sequence consisting of SEQ ID No.1 and at least one GABA<sub>B</sub>R2 subunit encoded by the oligonucleotide sequence consisting of SEQ ID No.3. In a more particular embodiment the isolated GABA<sub>B</sub> receptor according to the invention, consists of the receptor protein expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone 20 on August 22, 2003 with accession number LMBP 6046CB.

"Functional GABA<sub>B</sub> receptor" refers to a GABA<sub>B</sub> receptor formed by co-expression of GABA<sub>B</sub>R2 and GABA<sub>B</sub>R1a in a cell, wherein said cell does not normally express the GABA<sub>B</sub> receptor, most preferably resulting in a heterodimer of GABA<sub>B</sub>R2 and GABA<sub>B</sub>R1a, where the functional GABA<sub>B</sub> receptor mediates at least one functional response when exposed to the GABA<sub>B</sub> receptor agonist GABA. Examples of functional responses are : pigment aggregation in *Xenopus melanophores*, negative modulation of cAMP levels, coupling to inwardly rectifying potassium channels, mediation of late inhibitory postsynaptic potentials in neurons, increases in potassium conductance, decreases in calcium conductance, MAPKinase activation, extracellular pH acidification, and other functional responses typical of G-protein coupled receptors. One skilled in the art would be familiar with a variety of methods of measuring the functional responses of G-protein coupled receptors such as the GABA<sub>B</sub> receptor (see, e. g., Lerner, 1994, Trends Neurosci.17: 142-146 [changes in pigment distribution in melanophore cells]; Yokomizo et al., 1997, Nature 387: 620-624 [changes in cAMP or calcium concentration; chemotaxis]; Howard et al., 1996, Science 273: 974-977 [changes in membrane currents in *Xenopus oocytes*]; McKee et al., 1997, Mol. Endocrinol. 11: 415-423 [changes in calcium concentration measured using the aequorin assay]; Offermanns & Simon, 1995, J. Biol. Chem. 270: 15175-15180 [changes in inositol phosphate levels]). Depending upon the cells in which heteromers of GABA<sub>B</sub>R1a and GABA<sub>B</sub>R2 are expressed, and thus the G-proteins with which the

functional GABA<sub>B</sub> receptor thus formed is coupled, certain of such methods may be appropriate for measuring the functional responses of such functional GABA<sub>B</sub> receptors. It is well within the competence of one skilled in the art to select the appropriate method of measuring functional responses for a given experimental system.

5

The term "compound", "test compound", "agent" or "candidate agent" as used herein can be any type of molecule, including for example, a peptide, a polynucleotide, or a small molecule that one wishes to examine for their activity as GABA<sub>B</sub> receptor agonist, and wherein said agent may provide a therapeutic advantage to the subject receiving it. The candidate agents can be administered to an individual by various routes, including, for example, orally or parenterally, such as intravenously, intramuscularly, subcutaneously, intraorbitally, intracapsularly, intraperitoneally, intrarectally, intracisternally or by passive or facilitated absorption through the skin, using for example a skin patch or transdermal iontophoresis, respectively. Furthermore the compound can be administered by injection, intubation or topically, the latter of which can be passive, for example, by direct application of an ointment, or active, for example, using a nasal spray or inhalant, in which case one component of the composition is an appropriate propellant. The route of administration of the compound will depend, in part, on the chemical structure of the compound. Peptides and polynucleotides, for example, are not particular useful when administered orally because they can be degraded in the digestive tract. However, methods for chemically modifying peptides, for example rendering them less susceptible to degradation are well known and include for example, the use of D-amino acids, the use of domains based on peptidomimetics, or the use of a peptoid such as a vinylogous peptoid.

The agent used in the screening method may be used in a pharmaceutically acceptable carrier. See, e.g., *Remington's Pharmaceutical Sciences*, latest edition, by E.W. Martin Mack Pub. Co., Easton, PA, which discloses typical carriers and conventional methods of preparing pharmaceutical compositions that may be used in conjunction with the preparation of formulations of the agents and which is incorporated by reference herein.

30

### Cells

As already outlined above, the present invention provides a cell line stably transfected with expression vectors that direct the expression of the GABA<sub>B</sub> receptor subunits GABA<sub>B</sub>R1a and GABA<sub>B</sub>R2 as defined hereinbefore. In particular CHO cells transfected with said expression vectors. Such expression vectors are routinely

35



constructed in the art of molecular biology and may involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression. Generally, any system or vector suitable to maintain, propagate or  
5 express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence, i.e. the polynucleotide sequences encoding either the human GABA<sub>B</sub>R1a or GABA<sub>B</sub>R2 subunit as defined hereinbefore, may be inserted into an expression system by any of a variety of well-known and routine techniques such as for example those set forth in Current Protocols in Molecular Biology, Ausbel et al.  
10 eds., John Wiley & Sons, 1997.

In a particular embodiment the CHO cells according to the invention are cotransfected with the commercially available expression vectors pcDNA3.1 comprising the polynucleotide sequences encoding for human GABA<sub>B</sub>R1a (SEQ ID  
15 No.:1) and human GABA<sub>B</sub>R2 (SEQ ID No.: 3) respectively. More preferably the present invention provides a hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone 20 on August 22, 2003 with the accession number LMBP 6046CB. This cell line is characterized in that the functional GABA<sub>B</sub> receptor in this CHO cell line  
20 has both a low and a high affinity binding site for GABA<sub>B</sub> receptor agonist. Using the cell line according to the invention, will not only allow compound screening, but also provides a useful tool for the characterization of the nature of the compound-receptor interaction, i.e. does it interact with the low or high affinity agonist binding site of the GABA<sub>B</sub> receptor.

25 For further details in relation to the preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, see for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press.

30

#### Assays

The present invention also provides an assay for a compound capable of interacting with the functional GABA<sub>B</sub> receptor of the present invention, which assay comprises:  
35 providing the GABA<sub>B</sub> receptor expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line of the present invention, contacting said receptor with a putative binding

compound; and determining whether said compound is able to interact with said receptor.

5 In one embodiment of the assay, the receptor or subunits of the receptor may be employed in a binding assay. Binding assays may be competitive or non-competitive. Such an assay can accommodate the rapid screening of a large number of compounds to determine which compounds, if any, are capable of binding to the polypeptides.

10 Within this context, the present invention provides a method to identify whether a test compound binds to an isolated GABA<sub>B</sub> receptor protein of the present invention, and is thus a potential agonist or antagonist of the GABA<sub>B</sub> receptor, said method comprising;

a) contacting cells expressing a functional GABA<sub>B</sub> receptor, wherein such cells do not normally express the GABA<sub>B</sub> receptor, with the test compound in the presence and absence of a compound known to bind the GABA<sub>B</sub> receptor, and

15 b) determine the binding of the test compound to the GABA<sub>B</sub> receptor using the compound known to bind to the GABA<sub>B</sub> receptor as a reference.

Binding of the test compound or of the compound known to bind to the GABA<sub>B</sub> receptor, hereinafter also referred to as reference compound, is assessed using art-known methods for the study of protein-ligand interactions. For example, such binding  
20 can be measured by employing a labeled substance or reference compound. The test compound or reference compound can be labeled in any convenient manner known in the art, *e.g.* radioactively, fluorescently or enzymatically. In a particular embodiment of the aforementioned method, the compound known to bind to the GABA<sub>B</sub> receptor, *a.k.a.* the reference compound is detectably labeled, and said label is used to determine  
25 the binding of the test compound to the GABA<sub>B</sub> receptor. Said reference compound being labeled using a radiolabel, a fluorescent label or an enzymatic label, more preferably a radiolabel. In a more particular embodiment, the present invention provides a method to identify whether a test compound binds to an isolated GABA<sub>B</sub> receptor protein, said method comprising the use of a compound known to bind to the  
30 GABA<sub>B</sub> receptor, wherein said reference compound is selected from the group consisting of <sup>3</sup>H-GABA, <sup>3</sup>H-baclofen, <sup>3</sup>H-3-APPA, <sup>3</sup>H-CGP542626 and <sup>3</sup>H-SCH50911.

Subsequently, more detailed assays can be carried out with those compounds found to bind, to further determine whether such compounds act as agonists or antagonists of the  
35 polypeptides of the invention.

Thus, in a further embodiment the present invention provides a method to identify GABA<sub>B</sub> receptor agonists said method comprising,

- a) exposing cells expressing a functional GABA<sub>B</sub> receptor, wherein such cells do not normally express the GABA<sub>B</sub> receptor, to a labeled agonists of GABA<sub>B</sub> in the presence and absence of the test compound, and
- b) determine the binding of the labeled agonist to said cells, where if the amount of binding of the labeled agonist is less in the presence of the test compound, then the compound is a potential agonist of the GABA<sub>B</sub> receptor. As already specified for the general binding assay above, the binding of the GABA<sub>B</sub> receptor agonists is assessed using art-known methods for the study of protein-ligand interactions. The label is generally selected from a radioactive label, a fluorescent label or an enzymatic label, in particular a radiolabel wherein the agonist is selected from the group consisting of <sup>3</sup>H-GABA, <sup>3</sup>H-baclofen and <sup>3</sup>H-3-APPA.

Similarly, the present invention provides a method to identify GABA<sub>B</sub> receptor antagonists said method comprising,

- a) exposing cells expressing a functional GABA<sub>B</sub> receptor, wherein said cells do not normally express the GABA<sub>B</sub> receptor, to a labeled antagonist of GABA<sub>B</sub> in the presence and absence of the test compound, and
- b) determine the binding of the labeled antagonist to said cells, where if the amount of binding of the labeled antagonist is less in the presence of the test compound, then the compound is a potential antagonist of the GABA<sub>B</sub> receptor. As already specified for the general binding assay above, the binding of the GABA<sub>B</sub> receptor antagonists is assessed using art-known methods for the study of protein-ligand interactions. The label is generally selected from a radioactive label, a fluorescent label or an enzymatic label, in particular a radiolabel wherein the antagonist is selected from the group consisting of <sup>3</sup>H-CGP542626 and <sup>3</sup>H-SCH50911.

In an alternative embodiment of the present invention, the aforementioned binding assays are performed on a cellular composition, i.e a cellular extract, a cell fraction or cell organelles comprising a GABA<sub>B</sub> receptor as defined hereinbefore. More in particular, the aforementioned binding assays are performed on a cellular composition, i.e. a cellular extract, a cell fraction or cell organelles comprising a GABA<sub>B</sub> receptor as defined hereinbefore, wherein said cellular composition, i.e. cellular extract, cell fraction or cell organelles, is obtained from cells expressing a functional GABA<sub>B</sub> receptor, wherein said cells do not normally express the GABA<sub>B</sub> receptor. More preferably, the cellular composition, i.e. cellular extract, cell fraction or cell organelles, is

obtained from the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone 20 on August 22, 2003 with the accession number LMBP 6046CB.

It is accordingly, an object of the present invention to provide a method for  
5 identifying a compound as a GABA<sub>B</sub> receptor agonist or antagonist, said method comprising;

a) administering the compound to a cellular composition of cells expressing a functional GABA<sub>B</sub> receptor, wherein said cells do not normally express the GABA<sub>B</sub> receptor, in the presence of a detectably labeled agonist or antagonist of the GABA<sub>B</sub>  
10 receptor; and

b) determine the binding of the labeled agonist or antagonist to said cellular composition, where if the amount of binding of the labeled agonist or antagonist is less in the presence of the test compound, then the compound is a potential agonist respectively  
15 antagonist of the GABA<sub>B</sub> receptor.

As already specified for the general binding assay above, the binding of the GABA<sub>B</sub> receptor agonist or antagonist is assessed using art-known methods for the study of protein-ligand interactions. The label is generally selected from a radioactive label, a fluorescent label or an enzymatic label, in particular a radiolabel wherein the agonist is  
20 selected from the group consisting of <sup>3</sup>H-GABA, <sup>3</sup>H-baclofen and <sup>3</sup>H-3-APPA and the antagonist is selected from the group consisting of <sup>3</sup>H-CGP542626 and <sup>3</sup>H-SCH50911. In a more specific embodiment the aforementioned binding assays are performed on a cellular composition consisting of the membrane fraction of cells according to the invention, in particular on membrane fractions of the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO  
25 cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone 20 on August 22, 2003 with the accession number LMBP 6046CB, using one or more of the aforementioned radiolabeled agonist and/or antagonists.

30 In a further embodiment the present invention provides a functional assay for identifying compounds that modulate the GABA<sub>B</sub>-receptor activity in the cells according to the invention. Such an assay is conducted using the cells of the present invention, i.e. cotransfected with the human GABA<sub>B</sub>R1a and human GABA<sub>B</sub>R2 subunits. The cells are contacted with at least one reference compound wherein the ability of said  
35 compound to modulate the GABA<sub>B</sub>-receptor activity is known. Thereafter, the cells are contacted with a test compound and determined whether said test compound modulates the activity of the GABA<sub>B</sub> receptor compared to the reference compound. A "reference

compound" as used herein refers to a compound that is known to bind and/or to modulate the GABA<sub>B</sub> receptor activity.

- 5 A compound or a signal that "modulates the activity" of a polypeptide of the invention refers to a compound or a signal that alters the activity of the polypeptide so that it behaves differently in the presence of the compound or signal than in the absence of the compound or signal. Compounds affecting modulation include agonists and antagonists. An agonist of the GABA<sub>B</sub> receptor encompasses a compound such as GABA, baclofen and 3 - APPA which activates GABA<sub>B</sub> receptor function.
- 10 Alternatively, an antagonist includes a compound that interferes with GABA<sub>B</sub> receptor function. Typically, the effect of an antagonist is observed as a blocking of agonist-induced receptor activation. Antagonists include competitive as well as non-competitive antagonists. A competitive antagonist (or competitive blocker) interacts with or near the site specific for agonist binding. A non-competitive antagonist or
- 15 blocker inactivates the function of the receptor by interacting with a site other than the agonist interaction site.

- In one embodiment the present invention provides a method for identifying compounds that have the capability to modulate GABA<sub>B</sub> receptor activity, said method comprising;
- 20 a) contacting cells expressing a functional GABA<sub>B</sub> receptor, wherein said cells do not normally express a functional GABA<sub>B</sub> receptor, with at least one reference compound, under conditions permitting the activation of the GABA<sub>B</sub> receptor;
- b) contacting the cells of step a) with a test compound, under conditions permitting the activation of the GABA<sub>B</sub> receptor, and
- 25 c) determine whether said test compound modulates the GABA<sub>B</sub> receptor activity compared to the reference compound.

- Methods to determine the capability of a compound to modulate the GABA<sub>B</sub> receptor activity are based on the variety of assays available to determine the functional response of G-protein coupled receptors (see above) and in particular on assays to determine the
- 30 changes in potassium currents, changes in calcium concentration, changes in cAMP and changes in GTPγS binding. Conditions permitting the activation of the GABA<sub>B</sub> receptor generally known in the art, for example in case of antagonist screening these conditions comprise the presence of a GABA<sub>B</sub> receptor agonist in the assay system.
- 35 Typical GABA<sub>B</sub> receptor agonists used in these activity assays are GABA, baclofen or 3-APPA. More particular in the GTPγS assay as outlined herein below, GABA is used

to activate the GABA<sub>B</sub> receptor in order to assess the capability of a test compound to inactivate the GABA<sub>B</sub> receptor protein.

5 In the aforementioned assay an increase of GTPγS binding in the presence of the test compound is an indication that the compound activates the GABA<sub>B</sub> receptor activity, and accordingly that said test compound is a potential agonist of the GABA<sub>B</sub> receptor protein. A decrease of GTPγS binding in the presence of the test compound is an indication that the compound inactivates the GABA<sub>B</sub> receptor protein and accordingly that said test compound is a potential antagonist of the GABA<sub>B</sub> receptor protein.

10

Particularly preferred types of assays include binding assays and functional assays which may be performed as follows:

Binding assays

15 Over-expression of the GABA<sub>B</sub> receptor expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line of the present invention may be used to produce membrane preparations bearing said receptor (referred to in this section as GABA<sub>B</sub> binding receptor for convenience) for ligand binding studies. These membrane preparations can be used in conventional filter-binding assays (eg. Using Brandel filter assay equipment) or in high  
20 throughput Scintillation Proximity type binding assays (SPA and Cytostar-T flashplate technology; Amersham Pharmacia Biotech) to detect binding of radio-labelled GABA<sub>B</sub> ligands (including <sup>3</sup>H-GABA, <sup>3</sup>H-baclofen, <sup>3</sup>H-3-APPA, <sup>3</sup>H-CGP542626, <sup>3</sup>H-SCH50911) and displacement of such radio-ligands by competitors for the binding site. Radioactivity can be measured with Packard Topcount, or similar instrumentation,  
25 capable of making rapid measurements from 96-, 384-, 1536- microtitre well formats. SPA/Cytostar-T technology is particularly amenable to high throughput screening and therefore this technology is suitable to use as a screen for compounds able to displace standard ligands.

30 Another approach to study binding of ligands to GABA<sub>B</sub> binding receptor protein in an environment approximating the native situation makes use of a surface plasmon resonance effect exploited by the Biacore instrument (Biacore). GABA<sub>B</sub> binding receptor in membrane preparations or whole cells could be attached to the biosensor chip of a Biacore and binding of ligands examined in the presence and  
35 absence of compounds to identify competitors of the binding site.

Functional assays

Since GABA<sub>B</sub> receptors belong to the family G-protein coupled receptors that are coupled to GIRK (inward rectifying potassium channels), potassium ion flux should result on activation of these receptors. This flux of ions may be measured in real time  
5 using a variety of techniques to determine the agonistic or antagonistic effects of particular compounds. Therefore, recombinant GABA<sub>B</sub> binding receptor proteins expressed in the cell lines of the present invention can be characterised using whole cell and single channel electrophysiology to determine the mechanism of action of compounds of interest. Electrophysiological screening, for compounds active at  
10 GABA<sub>B</sub> binding receptor proteins, may be performed using conventional electrophysiological techniques and when they become available, novel high throughput methods currently under development.

Given the presynaptic effect of GABA<sub>B</sub> receptor activation on Ca<sup>2+</sup> channels, in  
15 an alternative functional screen the modulatory effect of a compound is assessed through the changes in intracellular calcium. Calcium fluxes are measurable using several ion-sensitive fluorescent dyes, including fluo-3, fluo-4, fluo-5N, fura red and other similar probes from suppliers including Molecular Probes. The inhibition of calcium influx as a result of GABA<sub>B</sub> receptor activation can thus be characterised in  
20 real time, using fluorometric and fluorescence imaging techniques, including fluorescence microscopy with or without laser confocal methods combined with image analysis algorithms.

Another approach is a high throughput screening assay for compounds active as  
25 either agonists or modulators which affect calcium transients. This assay is based around an instrument called a FLuorescence Imaging Plate Reader (FLIPR®), Molecular Devices Corporation). In its most common configuration, it excites and measures fluorescence emitted by fluorescein-based dyes. It uses an argon-ion laser to produce high power excitation at 488 nm of a fluorophore, a system of optics to rapidly  
30 scan the over the bottom of a 96-/384-well plate and a sensitive, cooled CCD camera to capture the emitted fluorescence. It also contains a 96-/384-well pipetting head allowing the instrument to deliver solutions of test agents into the wells of a 96-/384-well plate. The FLIPR assay is designed to measure fluorescence signals from populations of cells before, during and after addition of compounds, in real time, from  
35 all 96-/384-wells simultaneously. The FLIPR assay may be used to screen for and characterise compounds functionally active at the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line.

A high throughput screening assay, specifically usefull to identify GABA<sub>B</sub> agonists could consist of an arrangement wherein hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cells, are loaded with an appropriate fluorescent dye, incubated with a test compound and after sufficient time to allow interaction (8 – 24 hours, typically 12-24 hours, in particular 24 hours.) the change in relative fluorescence units measured using an automated fluorescence plate reader such as FLIPR or Ascent Fluoroskan (commercially available from Thermo Labsystems, Brussel, Belgium).

- 10 In a further embodiment the functional assay is based on the change in GTPγS binding to the GABA<sub>B</sub> binding receptor. In particular using a competition bindig assay to determine the displacement of radiolabelled GTPγS. In general, this method to identify GABA<sub>B</sub>-receptor agonists comprises preparing a membrane fraction from cells expressing the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 heterodimer af the present invention,
- 15 contacting said membrane preparations with the compound to be tested in the presence of radiolabelled GTPγS, under conditions permitting the activation of the GABA<sub>B</sub> receptor, and detecting GTPγS binding to the membrane fraction. An increase in GTPγS binding in the presence of the compound is an indication that the compound activates the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 receptor. A decrease in GTPγS binding in the
- 20 presence of the compound is an indication that the compound inactivates the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 receptor. Preferably this GTPγS binding assay is performed on membrane fractions obtained from the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone 20 on August 22, 2003 with the accession number LMBP
- 25 6046CB. Further, the conditions permitting the activation of the GABA<sub>B</sub> receptor comprise the presence of a GABA<sub>B</sub> receptor agonist, such as for example GABA, baclofen and 3-APPA in the assay system. In particular GABA.

This and other functional screening assays will be provided in the examples hereinafter.


30

#### *GABA<sub>B</sub> receptor agonists*

In a further aspect the present invention provides GABA<sub>B</sub> receptor agonists identified using one of the aforementioned screening assays wherein said GABA<sub>B</sub> receptor agonists are represented by the compounds of formula (I)

35





the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

$=Z^1-Z^2=Z^3-Z^4=$  represents a divalent radical selected from the group consisting of

$$=N-CH=CH-N= \text{ (a)}, =N-CH=N-CH= \text{ (b)}, =CH-N=CH-N= \text{ (c)}$$
$$=CH-CH=CH-CH= \text{ (d), } =N-CH=CH-CH= \text{ (e), } =CH-N=CH-CH= \text{ (f),}$$
$$=CH-CH=N-CH= \text{ (g) and } =CH-CH=CH-N= \text{ (h);}$$

R<sup>1</sup> represents hydrogen, halo, hydroxyl, cyano, C<sub>1-6</sub>alkyl, CF<sub>3</sub>, amino or mono- or di(C<sub>1-4</sub>alkyl)amino;

R<sup>2</sup> represents hydrogen, C<sub>1-6</sub>alkyl or hydroxycarbonyl-C<sub>1-6</sub>alkyl-.

In particular those compounds of formula (I) wherein one or more of the following restrictions apply;

(i)  $=Z^1-Z^2=Z^3-Z^4=$  represents a divalent radical selected from the group consisting of

$$=N-CH=CH-N=$$
 (a),  $=N-CH=N-CH=$  (b),  $=CH-N=CH-N=$  (c) and
$$=CH-CH=CH-CH= (d);$$

(ii) R<sup>1</sup> represents halo, amino or mono- or di(C<sub>1-4</sub>alkyl)amino;

(iii)  $R^2$  represents butyric acid

Also of interest are those compounds of formula (I) wherein:

(i)  $R^1$  is attached at position  $Z^1$ ; and/or

(ii)  $=Z^1-Z^2=Z^3-Z^4=$  represents (a), (b) or (d), more preferably

$$=Z^1-Z^2=Z^3-Z^4=\text{represents (d).}$$

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C<sub>1-4</sub>alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like; C<sub>1-6</sub>alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, pentyl, hexyl, 3-methylbutyl, 2-methylpentyl and the like.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms, which the compounds of formula (I), are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic base addition salt forms which the compounds of formula (I), are able to form. Examples of such base addition salt forms are, for example, the sodium, potassium, calcium salts, and also the salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, *N*-methyl-*D*-glucamine, hydrabamine, amino acids, e.g. arginine, lysine.

Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.

The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I), as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.


The term stereochemically isomeric forms as used hereinbefore defines the possible different isomeric as well as conformational forms which the compounds of formula (I), may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or conformers of the basic molecular structure. All stereochemically isomeric forms of the compounds of formula (I), both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

The *N*-oxide forms of the compounds of formula (I), are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide.

The 7,8-dihydro-phenothiazine derivatives of the present invention are generally prepared as described by Nemeryuk M.P. et al., *Khimiko-Farmatsevticheskii Zhurnal* (1985), 19(8), 964-968. In brief, the known ortho-amino substituted (hetero)arene-thiols (II), are condensed with an appropriate 2-bromo-5,5-dimethyl-3-oxo-cyclohex-1-enylamino derivative (III), by heating the two reactants in a suitable solvent, such as ethanol or N-methylpyrrolidone. Standard work-up and purification gives the desired products of formula I (Scheme 1).

10

Scheme 1




Wherein  $=Z^1-Z^2=Z^3-Z^4=$ , R<sup>1</sup> and R<sup>2</sup> are defined as for the compounds of formula (I) hereinbefore.

15

The appropriate 2-bromo-5,5-dimethyl-3-oxo-cyclohex-1-enylamino derivatives (III) can generally be obtained by amination of 5,5-dimethyl-1,3-cyclohexanedione with the appropriate amine of general formula (IV) under art known amination conditions, followed by bromination with N-bromosuccinimide (Scheme 2).

20


Scheme 2



Wherein R<sup>2</sup> is defined as for the compounds of formula (I) hereinbefore.

For those compounds of formula (I) where R<sup>2</sup> represents butyric acid, hereinafter referred to as the compounds of formula (I'), the compounds are obtained by condensing the ortho-amino substituted (hetero)arene-thiol (II) with 4-(2-bromo-5,5-dimethyl-3-oxo-cyclohex-1-enylamino)-butyric acid or an ester derivative such as a t-butylester (V) using art known conditions, such as for example by heating the two reactants in a suitable solvent, such as ethanol or N-methylpyrrolidone. Standard work-up and purification gives the desired products, or the ester derivative, which can be

hydrolyzed under acidic or basic conditions to give the required butyric acids (I') (Scheme 3).



5

Further examples for the synthesis of compounds of formula (I) using the above mentioned synthesis method is provided in the experimental part hereinafter.

- 10 Where necessary or desired, any one or more of the following further steps in any order may be performed:
- (i) removing any remaining protecting group(s);
  - (ii) converting a compound of formula (I) or a protected form thereof into a further compound of formula (I) or a protected form thereof;
  - 15 (iii) converting a compound of formula (I) or a protected form thereof into a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
  - (iv) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into a compound of formula (I) or a protected form thereof;
  - 20 (v) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into another *N*-oxide, a pharmaceutically acceptable addition salt a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof.

25

It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting groups.

- 30 Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydropyranyl. Suitable protecting groups for amino include tert-butoxycarbonyl or

benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C<sub>(1-6)</sub>alkyl or benzyl esters.

5 The protection and deprotection of functional groups may take place before or after a reaction step.

The use of protecting groups is fully described in 'Protective Groups in Organic Synthesis' 3<sup>rd</sup> edition, T W Greene & P G M Wutz, John Wiley & Sons Inc. (June 1999).

10

Additionally, the N-atoms in compounds of formula (I) can be methylated by art-known methods using CH<sub>3</sub>-I in a suitable solvent such as, for example 2-propanone, tetrahydrofuran or dimethylformamide.

15 Some of the intermediates and starting materials as used in the reaction procedures mentioned hereinabove are known compounds and may be commercially available or may be prepared according to art-known procedures.

#### *Method of Treatment*

20 The present invention also provides the use of a compound identified as a GABA<sub>B</sub> receptor activity modulator, using one of the aforementioned assays, in particular the compounds of formula (I) as described hereinbefore, in the manufacture of a medicament for the treatment an indication such as stiff man syndrome, gastroesophageal reflux, neuropathic pain, incontinence and treatment of cough and  
25 cocaine addiction. In particular for use in the manufacture of a medicament to reduce transient lower esophageal sphincter relaxations (TLESR). It is thus an object of the present invention to provide a method for the treatment of a warm-blooded animal, for example, a mammal including humans, suffering from an indication such as stiff man syndrome, gastroesophageal reflux, neuropathic pain, incontinence and treatment of  
30 cough and cocaine addiction, in particular TLESR.

Said method comprising administering to a warm-blooded animal in need thereof an effective amount of a compound identified as a GABA<sub>B</sub> receptor modulator using a method according to the invention. In particular the systemic or topical administration of an effective amount of a compound according to the invention, to  
35 warm-blooded animals, including humans.

Such agents may be formulated into compositions comprising an agent together with a pharmaceutically acceptable carrier or diluent. The agent may in the form of a physiologically functional derivative, such as an ester or a salt, such as an acid addition salt or basic metal salt, or an N or S oxide. Compositions may be formulated for any suitable route and means of administration. Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, inhalable, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The choice of carrier or diluent will of course depend on the proposed route of administration, which, may depend on the agent and its therapeutic purpose. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, acetylated triglycerides and the like, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Gennaro et al., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 18th Edition, 1990.

The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

- 5 Dosage forms or compositions containing active ingredient in the range of 0.25 to 95% with the balance made up from non-toxic carrier may be prepared.

For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example,  
10 pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium crosscarmellose, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 1%-95% active ingredient, more  
15 preferably 2-50%, most preferably 5-8%.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension  
20 in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate,  
25 triethanolamine sodium acetate, etc.

The percentage of active compound contained in such parental compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.1% to 10% in  
30 solution are employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably, the composition will comprise 0.2-2% of the active agent in solution.

35 Throughout this description the terms "standard methods", "standard protocols" and "standard procedures", when used in the context of molecular biology techniques, are to be understood as protocols and procedures found in an ordinary laboratory

manual such as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.

5

This invention will be better understood by reference to the Experimental Details that follow, but those skilled in the art will readily appreciate that these are only illustrative of the invention as described more fully in the claims that follow thereafter. Additionally, throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.

10

## EXPERIMENTAL PART

### I SYNTHESIS OF GABA<sub>B</sub> AGONISTS

15

In the procedures described hereinafter the following abbreviations were used : "DIPE" stands for diisopropylether; "EtOAc" stands for ethyl acetate.


For some chemicals the chemical formula was used, e.g. CH<sub>3</sub>CN for acetonitrile, NH<sub>3</sub> for ammonia, CH<sub>2</sub>Cl<sub>2</sub> for dichloromethane, MgSO<sub>4</sub> for magnesium sulfate, and HCl for

20 hydrochloric acid.

#### A. Preparation of the intermediates


##### Example A.1

Preparation of



intermediate 1

and



intermediate 2


4-Aminobutanoic acid 1,1-dimethylethyl ester [50479-22-6] (14g, 0.087mol) and 5,5-dimethyl-1,3-cyclohexanedione [126-81-8] (12.26g, 0.087mol) were dissolved in trichloromethane (250 ml) and *N,N*-diethylethanamine (0,5ml) was added. The reaction mixture was stirred for 3 days and subsequently washed with three portions of 250ml of water. The organic layer was dried on MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was recrystallised in DIPE/ CH<sub>3</sub>CN to give 18.6g (76%) of intermediate 1.

30



This product was taken up in methanol (250 ml) and water (100 ml). 1-Bromo-2,5-pyrrolidinedione (11.8g, 0.066 mol) was added portionwise over a 30 minutes period. After stirring for an additional hour, 500 ml water was added. The mixture was extracted with three portions of dichloromethane. The combined organic layers were dried on  $\text{MgSO}_4$  and concentrated under reduced pressure to yield 22g (92%) of intermediate 2.


In a similar way was also prepared :



intermediate 3

#### Example A.2

Preparation of




intermediate 4

A mixture of 5,6-diamino-4(1H)-pyrimidinethione [2846-89-1] (0.0027 mol) and intermediate 2 (0.0027 mol) in ethanol (q.s.) was stirred for 2 hours at 85°C. The reaction mixture was filtered and the solvent was evaporated. The residue was purified by high-performance liquid chromatography. The product fractions were collected and the solvent ( $\text{CH}_3\text{CN}$ ) was evaporated. The aqueous layer was extracted with EtOAc. The organic layer was separated, dried ( $\text{MgSO}_4$ ), filtered and the solvent was evaporated, yielding 0.400 g (30%) of intermediate 4.

#### Example A.3

Preparation of




intermediate 5

A mixture of 2-aminobenzothiol [137-07-5] (0.004 mol) and intermediate 2 (0.004 mol) in 1-methyl-2-pyrrolidinone [872-50-4] (15 ml) was stirred for 1 hour at 140°C. The reaction mixture was cooled and the layers were separated with EtOAc/ $\text{H}_2\text{O}(\text{NH}_3)$ . The organic layer was dried ( $\text{MgSO}_4$ ), filtered and the solvent was evaporated. The residue was purified by high-performance liquid chromatography. The product fractions were collected and the solvent ( $\text{CH}_3\text{CN}$ ) was evaporated. The aqueous layer was extracted with EtOAc and then the organic layer was dried ( $\text{MgSO}_4$ ), filtered off and the solvent was evaporated, yielding 0.6 g (40 %) of intermediate 5.

B. Preparation of the compoundsExample B.1

Preparation of




compound 2

A mixture of intermediate 4 (0.001 mol) in trifluoroacetic acid (5 ml) and dichloromethane (5 ml) was stirred for 1 hour at room temperature. The reaction mixture was dried under a stream of nitrogen. The resulting residue was suspended in diethyl ether. The desired product was filtered off and dried (vacuo) at 30°C, yielding 0.120 g (23 %) of trifluoroacetic acid salt of compound 2.


In a similar way were also prepared :

The hydrobromic acid salt of



compound 1


and the trifluoroacetic acid salt of



compound 4

10 Example B.2

Preparation of



compound 3

A mixture of intermediate 5 (0.00155 mol) in trifluoroacetic acid (5 ml) and dichloromethane (5 ml) was stirred for 20 hours at room temperature. The reaction mixture was dried under a stream of nitrogen. The resulting residue was solidified in diethyl ether. The desired product was filtered off and dried (vacuo) at 30°C, yielding 0.320 g (67 %) of trifluoroacetic acid salt of compound 3.

II DEVELOPMENT OF GABA<sub>B</sub>-CHO-K1 CELLS

## MATERIAL AND METHODS

20

*Permanent transfection of GABABR1a and GABABR2 in CHO-K1 cells using Lipofectamine PLUS:*

CHO-cells were transfected with hGABABR1a/pcDNA3.1. Monoclonal stable R1a-expressing cells were transfected with hGABABR2/pcDNA3.1Hygro+. Selection of clones occurred with 800 µg geneticin + 800 µg hygromycin/ml.

5 *Membrane preparation:*

Butyrate-stimulated (5 mM final) cells were scraped, after a short rinse with PBS, in 50 mM TrisHCl pH7.4 and centrifuged at 23500 g for 10 min. at 4°C. The pellet was homogenised in 5 mM TrisHCl pH 7.4 by Ultra-Turrax (24000 rpm) followed by centrifugation at 30000 g for 20 min. at 4°C. The resulting pellet was resuspended in  
10 50 mM TrisHCl pH 7.4 and rehomogenised. Protein concentration was determined using the Bradford method.

*GTPγ35S activation assay:*

10 µg membrane prep was incubated in 250 µl in 20 mM Hepes pH 7.4, 100 mM NaCl,  
15 3 mM MgCl<sub>2</sub>, 0.25 nM GTPγ35S, 3 µM GDP, 10 µg saponin/ml, with or without 1mM GABA (basal activity in absence of baclofen) at 37°C for 20 min. Filtration was carried out onto 96-well GF/B filter plate in Harvester (Packard). Filters were rinsed 6 times with cold 10 mM phosphate buffer pH 7.4, and dried overnight before addition of 30 µl Microscint O, and measurement in Topcount (Packard, 1min./well).

20

*3H-agonist binding:*

30 - 60 µg membrane prep was incubated in 50 mM TrisHCl pH 7.4, 2.5 mM CaCl<sub>2</sub>, 10 nM 3H-GABA or 20 nM 3H-baclofen in 500 µl at 20°C. Non-specific binding was determined in the presence of 100 µM baclofen. After 90 minutes the mixture was  
25 transferred onto 96-well GF/B filterplate by Harvester (Packard). Filters were rinsed 6 times with cold 50 mM TrisHCl pH 7.4, 2.5 mM CaCl<sub>2</sub>, and dried overnight before addition of 30 µl Microscint O, and measurement in Topcount (Packard, 1min./well).

RESULTS

30

*GTPγ<sup>35</sup>S activation assay*

In membranes of stably hGABABR1a-transfected CHO-cells, we measured binding of the antagonist 3H-CGP54626. hGABABR2 was co-transfected in those R1a-clones with the highest antagonist binding. After subcloning stable clones were obtained  
35 showing functional activity in GTPγ35S-binding assay upon stimulation of membranes

by GABA, wherein said activity was potentiated in the presence of the positive modulator CGP7930 (Urwylers S., *et al.*, 2001, *Molecular Pharmacology*60:963-971) (fig. 1).

#### 5 Agonist Filter Binding Assay

An agonist filter binding assay has been developed in 96-well GF/B filterplate. The IC50 of known agonists and antagonists was determined (fig.2). While the stable hGABA<sub>B</sub>R1a or the transient hGABA<sub>B</sub>R2 monomeric GABA<sub>B</sub> receptor expressing cells did not show any binding to the agonists 3H-GABA or 3H-baclofen (data not shown), unexpectedly, in our hGABABR1a/R2 heterodimeric clone agonist binding was detected with both ligands. The Kd for 3H-baclofen, 3H-GABA, and 3H-CGP54626 was determined in saturation experiments and compared well with published results obtained with tissue preparations (table 1).

Table 1

15	<b><sup>3</sup>H-baclofen</b>		
	Rat	132 nM	(Hill & Bowery, 1981)
	Dog cortex	28 nM	(J&JPRD, 2000)
	hGABA <sub>B</sub> R1aR2/CHO	30 nM	(our data, n=2))
20	<b><sup>3</sup>H-GABA</b>		
	Rat	77 nM	(Hill & Bowery, 1983)
	Rat	15-30 nM	(Cross & Horton, 1988)
	Pig	26 nM	(Facklam & Bowery, 1993)
25	Human	20-30 nM	(Cross & Horton, 1988)
	hGABA <sub>B</sub> R1aR2/CHO	10-30 nM	(our data, n=6)
	<b><sup>3</sup>H-CGP54626</b>		
	Rat	1.5 nM	(Bittiger et al., 1993)
30	Pig	1.35 nM	(Facklam & Bowery, 1993)
	hGABA <sub>B</sub> R1aR2/CHO	1.5 nM	(Green et al., 1993)
	hGABA <sub>B</sub> R1aR2/CHO	2.78 nM	(our data, n=1)

The order of potency for agonists was AMPA > GABA > baclofen, and for antagonists CGP54626 > SCH50911 (fig.2). The obtained IC50s were reproducible between different membrane preparations (fig.3)

Upon full library screening we identified some compounds with binding and signal transduction properties with comparable potencies as the reference compounds GABA and baclofen (table 2).







	BINDING ASSAY	SIGNAL TRANSDUCTION
Chemistry	<sup>3</sup> H-GABA binding	GTP-γS binding
Reference compounds	pIC50	%Effect at 10 μM
 baclofen	6.90775	78.7021
 GABA	8.06026	79.2906
HTS hits		
 compound 1	7.1875	45.7275
 compound 2	6.82	40.95
 compound 3	6.43	24.44
 compound 4	6.87	61.93

Table 2 : pIC<sub>50</sub> and % effect in the GABA ligand binding, and GTPγS signal transduction assays for reference compounds and HTS hits.

- Agonist centrifugation Binding Assay* In an alternative binding assay the non-bound ligand was separated from the membranes by centrifugation instead of filtration. The assay was performed according to the earlier described filter binding assay, with the difference that the non-bound ligand was separated from the membranes by centrifugation in a microcentrifuge at 12500 rpm for 10 minutes. The supernatant was discarded, the pellet was rinsed with washing buffer and dissolved in 200 µl water. Scintillation fluid was added and the bound <sup>3</sup>H-GABA measured in Topcount (Packard, 1 min./well).
- In a saturation assay using increasing concentrations of <sup>3</sup>H-GABA (1 – 400 nM final) I was found that the GABA<sub>B</sub> receptor expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line, possess a low and a high affinity agonist binding site. Results of the saturation and scatchard analysis are summarized in Table 3. When the saturation assay was performed in the presence of 10 µM of the GABA<sub>B</sub> antagonist CGP54626 or one of the GABA<sub>B</sub> agonist of the present invention (compound 1), the <sup>3</sup>H-GABA binding to both the high and the low affinity site was blocked (figure 4a, b).

Table 3

	Mean (n=5)	SD
	nM	nM
<b>Bmax 1</b>	0.19	0.05
<b>Kd 1</b>	9.4	3.1
<b>Bmax 2</b>	0.76	0.24
<b>Kd 2</b>	401	224

## DISCUSSION

- To our knowledge, no earlier reports were made in literature of recombinant hGABA<sub>B</sub> receptor, showing agonist binding with a high and low affinity binding site in a filter binding assay. An HTS agonist filter binding screen has been developed using <sup>3</sup>H-GABA. We found reproducible K<sub>i</sub> values for known agonists and antagonists, independent of the membrane preparation.

It has in addition been demonstrated that the recombinant GABA<sub>B</sub> receptor has two agonist binding sites. One high affinity and one low affinity binding site. It is to be expected that high affinity agonists of the GABA<sub>B</sub> receptor will elicit a different response compared to the low affinity agonists. Hence, the cell line of the present  
5 invention not only allows to identify GABA<sub>B</sub> receptor agonists, but also provides a useful tool to characterize the nature of the compound receptor interaction.

Print Out (Original in Electronic Form)  
(This sheet is not part of and does not count as a sheet of the international application)

0-1	Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared Using	PCT Online Filing Version 3.50 (Build 0001.162)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	PRD2108-PCTf
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	paragraph number	p3. line 9
1-3	Identification of deposit	
1-3-1	Name of depositary institution	LMBP Vakgroep voor Moleculaire Biologie - Plasmidencollectie (BCCM/LMBP)
1-3-2	Address of depositary institution	Universiteit Gent, K.L. Ledeganckstraat 35, B-9000 Gent, Belgium
1-3-3	Date of deposit	22 August 2003 (22.08.2003)
1-3-4	Accession Number	LMBP 6046CB
1-4	Additional Indications	CHO-K1 h-GABA-b R1a/R2 clone 20
1-5	Designated States for Which Indications are Made	all designations

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	03 SEP 2004 (03. 09. 2004) yes
0-4-1	Authorized officer	

## FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the international Bureau on:	
0-5-1	Authorized officer	



**BELGIAN COORDINATED COLLECTIONS OF MICROORGANISMS - BCCM™  
LMBP-COLLECTION**

Page 1 of Form BCCM™/LMBP/BP/4/03-14 Receipt in the case of an original deposit

---

**Budapest Treaty on the International Recognition of the Deposit of Microorganisms for  
the Purposes of Patent Procedure**

**Receipt in the case of an original deposit issued pursuant to Rule 7.1 by the  
International Depositary Authority BCCM™/LMBP identified at the bottom of next page**

***International Form BCCM™/LMBP/BP/4/03-14***

---

**To : Name of the depositor :** Janssen Pharmaceutica N.V.

**Address :** Turnhoutseweg 30  
B-2340 Beerse

**I. Identification of the microorganism:**

**I.1 Identification reference given by the depositor:**

**CHO-K1 h-GABA-b R1a/R2 clone 20**

**I.2 Accession number given by the International Depositary Authority:**

**LMBP 6046CB**

**BELGIAN COORDINATED COLLECTIONS OF MICROORGANISMS - BCCM™  
LMBP-COLLECTION**Page 2 of Form BCCM™/LMBP/BP/4/03-14 Receipt in the case of an original deposit

---

**II. Scientific description and/or proposed taxonomic designation**

The microorganism identified under I above was accompanied by:

(mark with a cross the applicable box(es))

- |                                    |                              |  |
|------------------------------------|------------------------------|--|
| - a scientific description         | yes <input type="checkbox"/> | no <input checked="" type="checkbox"/> |
| - a proposed taxonomic designation | yes <input type="checkbox"/> | no <input checked="" type="checkbox"/> |


**III. Receipt and acceptance**

This International Depositary Authority accepts the microorganism identified under I above, which was received by it on (date of original deposit) : August 22, 2003

**IV. International Depositary Authority**

Belgian Coordinated Collections of Microorganisms (BCCM™)  
Laboratorium voor Moleculaire Biologie - Plasmidencollectie (LMBP)  
Universiteit Gent  
Technologiepark 927  
B-9052 Gent-Zwijnaarde, Belgium

Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):



Martine Vanhoucke  
BCCM/LMBP curator

Date : September 8, 2003

WHAT IS CLAIMED IS:

1. An isolated GABA<sub>B</sub> receptor protein comprising at least one GABA<sub>B</sub>R1a subunit and at least one GABA<sub>B</sub>R2 subunit, characterized in that said GABA<sub>B</sub> receptor has one high affinity agonist binding site and one low affinity agonist binding site.  
5
2. The GABA<sub>B</sub> receptor protein according to claim 1 wherein the GABA<sub>B</sub>R1a subunit is encoded by the oligonucleotide sequence consisting of SEQ ID No.1 and the GABA<sub>B</sub>R2 subunit is encoded by the oligonucleotide sequence consisting of SEQ ID N0.3.  
10
3. The GABA<sub>B</sub> receptor protein according to claims 1 or 2 wherein said receptor protein is expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone 20 on August 22, 2003 with the accession number LMBP 6046CB.  
15
4. Use of the GABA<sub>B</sub> receptor protein according to any one of claims 1 to 3 in a method to identify GABA<sub>B</sub> receptor agonists or antagonists.  
20
5. The hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB.
- 25 6. A method to identify whether a test compound binds to a GABA<sub>B</sub> receptor protein according to any one of claims 1 to 3, and is thus a potential agonist or antagonist of the GABA<sub>B</sub> receptor, said method comprising:  
a) contacting cells expressing a functional GABA<sub>B</sub> receptor, wherein such cells do not normally express the GABA<sub>B</sub> receptor, with the test compound in the presence and absence of a compound known to bind to the GABA<sub>B</sub> receptor, and  
30

b) determine the binding of the test compound to the GABA<sub>B</sub> receptor using the compound known to bind to the GABA<sub>B</sub> receptor as a reference.

7. A method according to claim 6, wherein the compound known to bind to the GABA<sub>B</sub> receptor is detectably labeled, and wherein said label is used to determine the binding of the test compound to the GABA<sub>B</sub> receptor.
8. A method according to claim 7 wherein the compound known to bind to the GABA<sub>B</sub> receptor is selected from the group consisting of <sup>3</sup>H-GABA, <sup>3</sup>H-baclofen, <sup>3</sup>H-3-APPA, <sup>3</sup>H-CGP542626 and <sup>3</sup>H-SCH50911.
9. A method to identify GABA<sub>B</sub> receptor agonists said method comprising,  
a) exposing cells expressing a functional GABA<sub>B</sub> receptor, wherein such cells do not normally express the GABA<sub>B</sub> receptor, to a labeled agonist of GABA<sub>B</sub> in the presence and absence of the test compound, and  
b) determine the binding of the labeled agonist to said cells,  
where if the amount of binding of the labeled agonist is less in the presence of the test compound, then the compound is a potential agonist of the GABA<sub>B</sub> receptor.
10. A method according to claim 10 wherein the labeled agonist is selected from the group consisting of <sup>3</sup>H-GABA, <sup>3</sup>H-baclofen and <sup>3</sup>H-3-APPA.
11. A method to identify GABA<sub>B</sub> receptor antagonists said method comprising,  
a) exposing cells expressing a functional GABA<sub>B</sub> receptor, wherein such cells do not normally express the GABA<sub>B</sub> receptor, to a labeled antagonist of GABA<sub>B</sub> in the presence and absence of the test compound, and  
b) determine the binding of the labeled antagonist to said cells,


where if the amount of binding of the labeled antagonist is less in the presence of the test compound, then the compound is a potential antagonist of the GABA<sub>B</sub> receptor.

- 5 12. A method according to claim 10 wherein the labeled antagonist is selected from the group consisting of <sup>3</sup>H-CGP542626 and <sup>3</sup>H-SCH50911.
13. A method for identifying a compound as a GABA<sub>B</sub> receptor agonist, said method comprising;
- 10 a) administering the compound to a cellular composition of the cells according to claim 5, in the presence of a detectably labeled GABA<sub>B</sub> receptor agonist; and
- b) determine the binding of the labeled agonist to said cellular composition,
- where if the amount of binding of the labeled agonist is less in the presence of the test compound, then the compound is a potential agonist of the GABA<sub>B</sub> receptor.
- 15 14. A method according to claim 13 wherein the cellular composition consists of a membrane fraction of the cells according to claim 5.
- 20 15. A method according to claims 13 or 14 wherein the labelled agonist is selected from the group consisting of <sup>3</sup>H-GABA, <sup>3</sup>H-baclofen and <sup>3</sup>H-3-APPA.
- 25 16. A method for identifying a compound as a GABA<sub>B</sub> receptor antagonist, said method comprising;
- a) administering the compound to a cellular composition of the cells according to claim 5, in the presence of a detectably labeled GABA<sub>B</sub> receptor antagonist; and
- b) determine the binding of the labeled antagonist to said cellular composition,

where if the amount of binding of the labeled antagonist is less in the presence of the test compound, then the compound is a potential antagonist of the GABA<sub>B</sub> receptor.

- 5     17. A method according to claim 16 wherein the cellular composition consists of a membrane fraction of the cells according to claim 5.
18. A method according to claims 16 or 17 wherein the labeled antagonist is selected from the group consisting of <sup>3</sup>H-CGP542626 and <sup>3</sup>H-SCH50911.
- 10     19. A method for identifying compounds that have the capability to modulate GABA<sub>B</sub> receptor activity, said method comprising;
- 15     a) contacting cells expressing a functional GABA<sub>B</sub> receptor, wherein said cells do not normally express a functional GABA<sub>B</sub> receptor, with at least one reference compound, under conditions permitting the activation of the GABA<sub>B</sub> receptor;
- 20     b) contacting the cells of step a) with a test compound, under conditions permitting the activation of the GABA<sub>B</sub> receptor, and
- 20     c) determine whether said test compound modulates the GABA<sub>B</sub> receptor activity compared to the reference compound.
20. A method according to claim 19 wherein the capability of the test compound to modulate the GABA<sub>B</sub> receptor activity is determined using one or more of the functional responses selected from the group consisting of changes in potassium currents, changes in calcium concentration, changes in cAMP and changes in GTPγS binding
- 25     21. A method for identifying compounds that have the capability to modulate GABA<sub>B</sub> receptor activity, said method comprising;
- 30     a) contacting a membrane fraction of the cells according to claim 5, with the compound to be tested in the presence of radiolabeled GTPγS, under conditions permitting the activation of the GABA<sub>B</sub> receptor; and
- 35     b) determine GTPγS binding to the membrane fraction, where an increase in GTPγS binding in the presence of the compound is an indication that the compound activates the GABA<sub>B</sub> receptor activity.

22. A method for identifying compounds that have the capability to modulate GABA<sub>B</sub> receptor activity, said method comprising;
- a) contacting a membrane fraction of the cells according to claim 5, with the compound to be tested in the presence of radiolabeled GTPγS, under conditions permitting the activation of the GABA<sub>B</sub> receptor; and
- b) determine GTPγS binding to the membrane fraction,
- where an decrease in GTPγS binding in the presence of the compound is an indicaton that the compound inactivates the GABA<sub>B</sub> receptor activity.
23. A method according to claims 21 or 22 wherein the conditions permitting the activation of the GABA<sub>B</sub> receptor comprise the presence of a GABA<sub>B</sub> receptor agonist.
24. A method according to claim 23 wherein the GABA<sub>B</sub> receptor agonist is selected from the group consisting of GABA, baclofen and 3-APPA.
25. Use of a compounds of formula (I)



- the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein;
- $=Z^1-Z^2=Z^3-Z^4=$  represents a divalent radical selected from the group consisting of
- $=N-CH=CH-N=$  (a),  $=N-CH=N-CH=$  (b),  $=CH-N=CH-N=$  (c)
- $=CH-CH=CH-CH=$  (d),  $=N-CH=CH-CH=$  (e),  $=CH-N=CH-CH=$  (f),
- $=CH-CH=N-CH=$  (g) and  $=CH-CH=CH-N=$  (h);
- $R^1$  represents hydrogen, halo, hydroxyl, cyano,  $C_{1-6}$ alkyl,  $CF_3$ , amino or mono- or di( $C_{1-4}$ alkyl)amino;
- $R^2$  represents hydrogen,  $C_{1-6}$ alkyl or hydroxycarbonyl- $C_{1-6}$ alkyl-, in the manufacture of a medicament for the treatment of an indication such as stiff man syndrome, gastroesophageal reflux, neuropathic pain, incontinence and treatment of cough and cocaine addiction.

26. Use of a compound of formula (I) in the manufacture of a medicament to reduce transient lower esophageal sphincter relaxations (TLESR).
27. A compound of formula (I) wherein  $=Z^1-Z^2-Z^3-Z^4=$  represents (a), (b) or (d),  
5 more preferably those compounds of formula (I) wherein  $=Z^1-Z^2-Z^3-Z^4=$  represents (d).
28. A compound according to claim 27 for use as a medicine.
- 10 29. Use of a compound according to claim 27 in the manufacture of a medicament to reduce transient lower esophageal sphincter relaxations (TLESR).



Fig 1




Fig 2




Fig 3




Fig 4a





Fig 4b

Scatchard analysis [3H]-GABA saturation curve  
on recombinant hGABA<sub>A</sub>R membranes



## SEQUENCE LISTING

5 <110> Janssen Pharmaceutica N.V.  
 <120> CHIMERIC GABA<sub>A</sub> RECEPTOR  
 10 <130> PRD 2108  
 <150> PCT/ EP03/10263  
 15 <151> 2003-09-12  
 <160> 4  
 20 <170> PatentIn version 3.1  
 <210> 1  
 <211> 2886  
 <212> DNA  
 25 <213> Homo sapiens  
 <220>  
 <221> CDS  
 <222> (1)..(2886)  
 30 <223>  
 <400> 1  
 atgttgctgc tgctgtact ggcgccactc ttcctccgcc ccccgggcgc gggcggggcg 60  
 cagaccccca acgccacctc agaaggttgc cagatcatac acccgccctg ggaagggggc 120  
 35 atcagggtacc ggggacctgac tcgggaccag gtgaaggcta tcaacttcct gccagtggac 180  
 tatgagattg agtatgtgtg ccggggggag cgcgaggttg tggggcccaa ggtccgcaag 240  
 tgccctggcca acggctcctg gacagatatg gacacacca gccgctgtgt ccgaatctgc 300  
 tccaagtctt atttgacctt ggaatatggg aagggttttc tgacgggtgg ggacctccca 360  
 40 gctctggagc gagcccggtt ggatttcccg tgtgaccccg acttccatct ggtgggcagc 420  
 tcccggagca tctgtagtca gggccagtgg agcaccacca agccccactg ccagggtgaat 480  
 cgaacgccac actcagaacg gcgcgcagtg tacatcgggg cactgtttcc catgagcggg 540  
 ggctggccag ggggcccaggc ctgccagccc gcggtggaga tggcgctgga ggacgtgaat 600  
 agcccgaggg acatcctgcc ggactatgag ctcaagctca tccaccacga cagcaagtgt 660  
 gatccaggcc aagccacca gtacctatat gagctgctct acaacgacct tatcaagatc 720  
 45 atccttatgc ctggctgcag ctctgtctcc acgctgggtg ctgaggctgc taggatgtgg 780  
 aacctcattg tgctttccta tggatccagc tcaccagccc tgtcaaaccg gcagcgtttc 840  
 cccactttct tccgaacgca cccatcagcc acactccaca accctacccg cgtgaaactc 900  
 tttgaaaagt ggggctggaa gaagattgct accatccagc agaccactga ggtcttcact 960  
 50 tggactctgg acgacctgga ggaacgagtg aaggaggctg gaattgagat tactttccgc 1020  
 cagagtttct tctcagatcc agctgtgccc gtcaaaaacc tgaagcgcca ggatgccga 1080  
 atcatcgtgg gacttttcta tgagactgaa gcccggaag ttttttgtga ggtgtacaag 1140  
 gagcgtctct ttgggaagaa gtacgtctgg ttcttcattg ggtgggtatg tgacaattgg 1200  
 ttcaagatct acgaccttcc tatcaactgc acagtggatg agatgactga ggcggtggag 1260  
 55 ggccacatca caactgagat tgtcatgctg aatcctgcca ataccgagc cattccaac 1320  
 atgacatccc aggaatttgt ggagaaacta accaagcgac tgaagagaca ccctgaggag 1380  
 acaggaggct tccaggaggc accgctggcc tatgatgcca tctgggctt ggccactggc 1440  
 ctgaacaaga catctggagg agcgggccgt tctgggtgtg ccttgaggga cttcaactac 1500  
 aacaaccaga ccattaccga ccaaatctac cgggcaatga actcttcgtc ctttgagggt 1560  
 gtctctggcc atgtgggtgt tgatgccagc ggctctcgga tggcatggac gcttatcgag 1620  
 60 cagcttcagg gtggcagcta caagaagatt ggctactatg acagacccaa ggatgatctt 1680  
 tcttggtcca aaacagataa atggattgga ggggtccccc cagctgacca gacctggtc 1740  
 atcaagacat tccgttctct gtcacagaaa ctctttatct ccgtctcagt tctctccagc 1800  
 ctgggcattg tcttagctgt tgtctgtctg tctttaaca tctacaactc acatgtccgt 1860  
 65 tatatccaga actcacagcc caacctgaac aacctgactg ctgtgggctg ctactggct 1920  
 tttagctgtg tcttccccct ggggctcgat gggtaccaca ttgggaggaa ccagtttctc 1980  
 ttcgtctgct agcccgccct ctggctcctg ggccctgggt ttagtctgtg ctacgggttc 2040  
 atgttcacca agatttgggt ggtccacacg gtcttcacaa agaaggaaga aaagaaggag 2100

5	tggaggaaga ctctggaacc ctggaagctg tatgccacag tgggcctgct ggtgggcatg 2160
	gatgtcctca ctctcgccat ctggcagatc gtggaccctc tgcaccggac cattgagaca 2220
	tttgccaagg aggaacctaa ggaagatatt gacgtctcta ttctgcccga gctggagcat 2280
	tgcagctcca ggaagatgaa tacatggctt ggcattttct atgggtacaa ggggctgctg 2340
	ctgctgctgg gaattcttct tgcttatgag accaagagtg tgtccactga gaagatcaat 2400
	gatcacccgg ctgtgggcat ggctatctac aatgtggcag tctgtgcct catcactgct 2460
	cctgtcacca tgattctgtc cagccagcag gatgcagcct ttgcctttgc ctctcttgc 2520
	atagttttct cctcctatat cactcttgtt gtgctctttg tgcccaagat ggcagggctg 2580
10	atcacccgag gggaatggca gtcggaggcg caggacacca tgaagacagg gtcacgacc 2640
	aacaacaacg agggaggagaa gtcccggtct tgggagaagg agaaccgtga actggaaaag 2700
	atcattgtct agaaagagga gcgtgtctct gaactgcgcc atcaactcca gtctcgagc 2760
	cagctccgct cccggcgcca cccaccgaca ccccagaaac cctctggggg cctgccagg 2820
	ggacccctg agccccccga cgggcttagc tgtgatggga gtcgagtgca tttgctttat 2880
15	aagtga 2886
	<210> 2
	<211> 961
	<212> PRT
20	<213> Homo sapiens
	<400> 2
25	MLLLLLLAPL FLRPPGAGGA QTPNATSEGC QIIHPPWEGG IRYRGLTRDQ VKAINFLPVD 60
	YEIEVVCGRG REVVGPKVRK CLANGSWTDM DTPSRCVRIC SKSYLTLENG KVFLTGGDLP 120
	ALDGARVDPR CDPDFHLVGS SRSICSQGW STPKPHCQVN RTPHSERRAV YIGALFPMSG 180
	GWPGGQACQP AVEMALEDVN SRRDILPDYE LKLIHDSKC DFGQATKYLY ELLYNDPIKI 240
	ILMPGCSVS TLVAEAARMW NLIVLSYGSS SPALSNRQRP PTFRTHPSA TLHNPTRVKL 300
	FEKWGWKKIA TIQQTTEVFT STLDLEERV KEAGIEITFR QSFSDPAVP VKNLKRQDAR 360
30	IIVGLFYETE ARKVFCVYK ERLFGKKYVW FLIGWYADNW PKIYDPSINC TVDEMTEAVE 420
	GHIITEIVML NPANTRISIN MTSQEFVEKL TKRLKRHPPE TGGFQEAPLA YDAIWALALA 480
	LNKTSGGGGR SGVRLEDFNY NNQITTDQIY RAMNSSSPEG VSGHVVDAS GSRMAWTLIE 540
	QLQGGSYKXI GYYDSTKDDL SWSKTDKIG GSPPADQTLV IKTFRPLSQK LPISVSVLSS 600
35	LGIVLAVVCL SFNIYNBHR YIONSQPNLN NLTAVGCSLA LAAVFPLGLD GYHIGRNQFP 660
	FVCQARLWLL GLGFSLGYS MFTKIWWVHT VFTKKEEKE WRKTLBPWKL YATVGLLVGM 720
	DVLTIAIWQI VDPLHRTIET FAKEEKPEDI DVSILPOLEH CSSRKMNTWL GIFYGYKGLL 780
	LLLGIFLAYE TKSVSTEKIN DHRAVGMAIY NVAVLCLITA PVTMILSSQQ DAAPAFASLA 840
	IVFSSYITLV VLFVPMRRL ITRGEWQSEA QDTMKTGSST NNNEEEKSRL LEKENRELEK 900
40	IIAEKEERVS ELRHQLQSRQ QLSRRHPPT PPEFSGGLPR GPPEPPDRLS CDGSRVHLLY 961
	K
	<210> 3
	<211> 2823
	<212> DNA
45	<213> Homo sapiens
	<220>
	<221> CDS
50	<222> (1)..(2823)
	<223>
	<400> 3
55	atggcttccc cgcgagctc cgggcagccc gggccgcgcg cgccgcgcgc accgcgcgcc 60
	gcgcgcctgc tactgtact gctgtgctgc ctgtgtgctc ctctggcgcc cggggcctgg 120
	ggctgggcgc gggggcgcgc cgggcgcgcg ccagcagcc cgccgctctc catcatgggc 180
	ctcatgcgcg tcaccaagga ggtggccaag ggcagcatcg ggcgcggtgt gctccccgcc 240
	gtggaactgg ccacgcagca gatccgcaac gagtcactcc tgcgccccta ctctctcgac 300
	ctgcggctct atgacacgga gtgcgacaac gcaaaagggt tgaagccctt ctacgatgca 360
60	ataaaatcac ggccgaacca ctgatgggtg tttggaggcg tctgtccatc cgtccatcc 420
	atcattgcag agtccctcca aggtcggaat ctggtgcagc tttcttttgc tgcaaccacg 480
	cctgttctag ccgataagaa aaaataccct tatttcttcc ggaccgtccc atcagacaat 540
	gcgggtgaatc cagccattct gaagttgctc aagcactacc agtggaaagc cgtgggcacg 600
	ctgacgcaag acgttcagag gttctctgag gtgcggaatg acctgactgg agttctgtat 660
65	ggcagaggaca ttgagatttc agacaccgag agcttclcca acgatccctg taccagtgtc 720
	aaaaagctga aggggaatga tgtgcggatc atccttgccc agtttgacca gaatatggca 780
	gcaaaagtgt tctgttgtgc atacgaggag aacatgtatg gtagtaaata tcagtggatc 840
	attccgggct ggtacagacc ttcttggtag gacgaggtgc acacggaagc caactcatcc 900
	cgctgcctcc ggaagaatct gcttgcgtcc atggagggtc acattggcgt ggatttcgag 960
70	cccttgagct ccaagcagat caagaccate tcaggaaaga tccacagca gtagtagaga 1020
	gagtacaaca acnagcggtc aggcgtgggg cccagcaagt tccacgggta cgctacgat 1080
	ggcatctggg tcatcgccaa gacactgcag agggccatgg agacactgca tgccagcagc 1140

	cggcaccagc	ggatccagga	cttcaactac	acggaccaca	cgctgggcag	gatcatcctc	1200
	aatgccatga	acgagaccaa	cttcttcggg	gtcacgggtc	aagtgtgat	coggaatggg	1260
	gagagaatgg	ggaccattaa	atttactcaa	tttcaagaca	gcagggaggt	gaagggtggga	1320
5	gagtacaacg	ctgtggccga	cacactggag	atcatcaatg	acaccatcag	gttccaagga	1380
	tcgcgaaccac	caaaagacaa	gaccatcatc	ctggagcagc	tgcggaagat	ctccctacct	1440
	ctctacagca	tcctctctgc	cctcaccatc	ctcgggatga	tcattggccag	tgctttttctc	1500
	ttcttcaaca	tcaagaaccg	gaatcagaag	ctcataaaga	tgctcagatcc	atacatgaac	1560
	aacctttatca	tccttggagg	gatgctctcc	tatgcttcca	tatttctctt	tgcccttgat	1620
10	ggatcccttg	tctctgaaaa	gacctttgaa	acactttgca	ccgtcaggac	ctggattctc	1680
	accgtgggct	acacgaccgc	ttttggggcc	atgtttgcaa	agacctggag	agtccacgcc	1740
	atcttcaaaa	atgtgaaaa	gaagaagaag	atcatcaagg	accagaaact	gcttltgac	1800
	gtggggggca	tgctgctgat	cgacctgtgt	atcctgatct	gctggcaggc	tgaggacccc	1860
	ctgcgaagga	cagtggagaa	gtacagcatg	gagccggacc	cagcaggacg	ggatatctcc	1920
	atccgccttc	tcctggagca	ctgtgagaac	acccatcatga	ccatctggct	tggtcatctc	1980
15	tatgcctaca	agggacttct	catgttgttc	ggttgtttct	tagcttggga	gacccgcaac	2040
	gtcagcatcc	ccgcactcaa	cgacagcaag	tacatcgga	tgagtgtcta	caactggggg	2100
	atcatgtgca	tcacggggc	cgctgtctcc	ttcctgaccc	gggaccagcc	caatgtgcag	2160
	ttctgcatcg	tggtctctgg	catcatcttc	tcagcaccca	tcacctctg	cctggtattc	2220
	gtgccgaagc	tcacaccct	gagaacaaac	ccagatgcag	caacgcagaa	caggcgattc	2280
20	cagttcactc	agaatcagaa	gaaagaagat	tctaaaacgt	ccacctcggt	caccagtgtg	2340
	aaccaagcca	gcacatccc	cctggagggc	ctacagtcag	aaaaccatcg	cctgcgaatg	2400
	aagatcacag	agctggataa	agacttgga	gaggtcacca	tgacagctga	ggacacacca	2460
	gaaaagacca	cctacattaa	acagaaccac	taccaagagc	tcaatgacat	cctcaacctg	2520
25	ggaaacttca	ctgagagcac	agatggagga	aaggccattt	taaaaaatca	cctcgatcaa	2580
	aatccccagc	tacagtggaa	cacaacagag	ccctctcgaa	catgcaaaaga	tcctatagaa	2640
	gatataaact	ctccagaaca	catccagcgt	cggtgtctcc	tccagctccc	catcctccac	2700
	cacgcctacc	tcccatccat	cgaggggcgt	gacgccagct	gtgtcagccc	ctgcctcagc	2760
	ccacccgcc	gccccgcc	cagacatgtg	ccacctcct	tccgagtc	ggtctcgggc	2820
30	ctg						2823
	<210>	4					
	<211>	941					
	<212>	PRT					
35	<213>	Homo sapiens					
	<400>	4					
	MASPRSSGQP	GPPPPPPPPP	ARLLLLLLLP	LLLPLAPGAW	GWARGAPRPP	PSSPPLSIMG	60
40	LMPLTKEVAK	GSIGRGVLP	VELAIEQIRN	ESLLRPYFLD	LRLYDTECDN	AKGLKAFYDA	120
	IKYGNHLMV	FGGVCPSVTS	IIAESLQGNW	LVQLSFAATT	PVLADKKKYP	VFFRTVPVSDN	180
	AVNPAIKLL	KHYQWKRVGT	LTQDVQRFSE	VRNDLTGVLY	GEDIEISDTE	SFSNDPCTSV	240
	KKLKGNDVRI	ILGFQDNMA	AKVPCCAYZE	NMYGSKYQWI	IPGWYEPSWW	EQVHTEANSS	300
	RCLRKNLLAA	MEGYIGVDFE	PLSSKQIKTI	SGKTPQQYER	EYNNKRSVG	PSKPHGYAYD	360
	GIWVIAKTLQ	RAMETLHASS	RHQRIQDFNY	TDHTLGRILL	NAMNETNFFG	VTGQVVRFRG	420
45	ERMGTIKFTQ	FQDSREVKVG	EYNAVADTLE	IINDTIRFOG	SEPPKDKTII	LEQLRKISLP	480
	LYSILSALTI	LGMIMASAFI	FFNIKRNQK	LKMSPPYMN	NLILGGMLS	YASIFLGLD	540
	GSEFVSEKTFE	TLCTVRTWIL	TVGYTTAFGA	MFAKTWRVHA	IFKNVKKKK	IKDQKLLVI	600
	VGGMLLIDL	ILICWQAVDP	LRRTEVKYSM	EPDPAGRDIS	IRPLLEHCEN	THMTIWLGI	660
	YAYKGLMLF	GCFLAWETRN	VSIPALNDSK	YIGMSVYNVG	IMCIIGAAVS	FLTRDQPNVQ	720
50	FCIVALVIF	CSTITLCLVF	VPKLITLRTN	PDAATQNRFF	QFTQNKQKED	SKTSTSVTSV	780
	NQASTSRLEG	LQSENHRLRM	KITELDKDLE	EVTMQLQDTP	EKTTYIKQNH	YQELNDILNL	840
	GNFTSTDDG	KAILKNHLDQ	NPQLQWNTTE	PSRTCKDPIE	DINSPEHIQ	RLSLQLPILH	900
	HAYLPSIGGV	DASCVSPCVS	PTASPRHRHV	PFSFRVMVSG	L		941

55



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number  
**WO 2005/026208 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/705**,  
G01N 33/94, C12N 5/10, C07D 471/00, 513/00, 513/04,  
279/18, A61K 31/5415, 31/542

Alfonsine, Astrid [BE/BE]; Janssen Pharmaceutica N.V.,  
Turnhoutseweg 30, B-2340 Beerse (BE). **GIJSEN, Hen-**  
**ricus, Jacobus, Maria** [NL/NL]; Janssen Pharmaceutica  
N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(21) International Application Number:

PCT/EP2004/052029

(74) Common Representative: **JANSSEN PHARMACEU-**  
**TICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(22) International Filing Date:

3 September 2004 (03.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP03/10263

12 September 2003 (12.09.2003) EP

(71) Applicant (for all designated States except US):  
**JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turn-  
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **SMANS, Karine,**

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: CHIMERIC GABAB RECEPTOR



(57) Abstract: The present invention provides an isolated GABA<sub>B</sub> receptor protein comprising at least one GABA<sub>B</sub>R1a subunit and at least one GABA<sub>B</sub>R2a subunit, characterized in that said GABA<sub>B</sub> receptor has one high affinity agonist binding site and one low affinity agonist binding site. In particular the isolated recombinant GABA<sub>B</sub> receptor protein expressed by the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB. It is thus an object of the present invention to provide the hGABA<sub>B</sub>R1a/GABA<sub>B</sub>R2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB. The invention also provides the use of the aforementioned cell line in a method to identify GABA<sub>B</sub> receptor agonists using a functional or a binding assay.



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

IT, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW. ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

#### (88) Date of publication of the international search report:

25 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/052029

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 G01N33/94 C12N5/10 C07D471/00 C07D513/00  
 C07D513/04 C07D279/18 A61K31/5415 A61K31/542

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K G01N C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, CHEM ABS Data, WPI Data, PAJ, Sequence Search

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GREEN ANDREW ET AL: "Characterization of (3H)-CGP54626A binding to heterodimeric GABAB receptors stably expressed in mammalian cells" BRITISH JOURNAL OF PHARMACOLOGY, vol. 131, no. 8, December 2000 (2000-12), pages 1766-1774, XP001105031 ISSN: 0007-1188 the whole document	1-24
X	WISE A ET AL: "CALCIUM SENSING PROPERTIES OF THE GABAB RECEPTOR" NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 38, no. 11, November 1999 (1999-11), pages 1647-1656, XP000865720 ISSN: 0028-3908 the whole document	1-24

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

23 February 2005

Date of mailing of the international search report

24. 06. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Valcarcel, R

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/052029

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-24

GABAB receptors having at least one GABABR1a and one GABABR2 subunit and methods involving said receptors  
CHO cell line expressing hGABABR1a and hGABABR2, and methods for identifying GABAB agonists and antagonists involving the use of said cell line  
Other methods to identify GABAB agonists and antagonists as defined in claims 9-12, 19, and 20

1.1. claims: 1-4,6-8

GABAB receptors having at least one GABABR1a and one GABABR2 subunit and methods involving said receptors

1.2. claims: 5,13-18,21-24

CHO cell line expressing hGABABR1a and hGABABR2, and methods for identifying GABAB agonists and antagonists involving the use of said cell line

1.3. claims: 9-12,19,20

Other methods to identify GABAB agonists and antagonists as defined in claims 9-12, 19, and 20  
---

2. claims: 25-29

Compounds as defined in claim 27 (formula I), and use of compounds as defined in claims 25, 28 and 29 in the manufacture of medicaments  
---

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/052029

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LANNEAU CHRISTOPHE ET AL: "Gabapentin is not a GABAB receptor agonist" NEUROPHARMACOLOGY, vol. 41, no. 8, December 2001 (2001-12), pages 965-975, XP001181057 ISSN: 0028-3908 the whole document -----	1-24
X	MARTIN AMANDA ET AL: "Pharmacological analysis of human GABAB (1a,2) and GABAB (1b,2) heterodimers expressed in CHO cells: Allosteric modulation of agonists and antagonists by Ca <sup>2+</sup> " BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. Proceedings Supplement, January 2000 (2000-01), page 82P, XP009030031 Meeting of the British Pharmacological Society;Cambridge, England, UK; January 05-07, 2000 ISSN: 0007-1188 the whole document -----	1-24
X	WO 00/73788 A (MERCK FROSST CANADA INC ;NEIL GARY O (CA); NG GORDON (CA)) 7 December 2000 (2000-12-07) the whole document -----	1-24
X	CUI M ET AL: "IN VITRO CHARACTERIZATION OF GABAB RECEPTORS AND GABAPENTIN EFFECT." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, page Abstract No. 896.15, XP009029475 32nd Annual Meeting of the Society for Neuroscience;Orlando, Florida, USA; November 02-07, 2002 the whole document -----	1-24
X	NG GORDON Y K ET AL: "gamma-Aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action" MOLECULAR PHARMACOLOGY, vol. 59, no. 1, January 2001 (2001-01), pages 144-152, XP002213218 ISSN: 0026-895X the whole document -----	1-24
X	WO 01/98779 A (MERCK FROSST CANADA INC ;NG GORDON (CA)) 27 December 2001 (2001-12-27) the whole document -----	1-24

-/--

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/052029

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRAEUNER-OSBORNE H ET AL: "FUNCTIONAL PHARMACOLOGY OF CLONED HETERODIMERIC GABAB RECEPTORS EXPRESSED IN MAMMALIAN CELLS" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 128, no. 7, December 1999 (1999-12), pages 1370-1374, XP000884864 ISSN: 0007-1188 the whole document -----	1-24
X	WO 99/51636 A (STORMANN THOMAS M ;BUSBY JAMES G (US); GARRETT JAMES E (US); NPS P) 14 October 1999 (1999-10-14) the whole document -----	1-24
X	US 6 465 213 B1 (EKSTRAND JONAS) 15 October 2002 (2002-10-15) the whole document -----	1-24
X	WO 99/40114 A (MERCK FROSST CANADA INC ;NG GORDON YIU KON (CA); BONNERT TIMOTHY P) 12 August 1999 (1999-08-12) the whole document -----	1-24
X	WO 00/14222 A (FRASER NEIL JAMES ;MARSHALL FIONA HAMILTON (GB); WISE ALAN (GB); G) 16 March 2000 (2000-03-16) the whole document -----	1-24
X	US 2002/045742 A1 (BOROWSKY BETH ET AL) 18 April 2002 (2002-04-18) the whole document -----	1-24
Y	KAUPMANN K ET AL: "HUMAN GAMMA-AMINOBUTYRIC ACID TYPE B RECEPTORS ARE DIFFERENTIALLY EXPRESSED AND REGULATE INWARDLY RECTIFYING K+ CHANNELS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, December 1998 (1998-12), pages 14991-14996, XP000867019 ISSN: 0027-8424 cited in the application the whole document -----	1-24
	----- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/052029

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WHITE J H ET AL: "HETERODIMERIZATION IS REQUIRED FOR THE FORMATION OF A FUNCTIONAL GABAB RECEPTOR"</p> <p>NATURE, MACMILLAN JOURNALS LTD. LONDON, GB,</p> <p>vol. 396, 17 December 1998 (1998-12-17), pages 679-682, XP000993024</p> <p>ISSN: 0028-0836</p> <p>cited in the application</p> <p>the whole document</p> <p>-----</p>	1-24
X	<p>HIRST WARREN D ET AL: "Pharmacological characterisation of a cell line expressing GABAB1b and GABAB2 receptor subunits."</p> <p>BIOCHEMICAL PHARMACOLOGY,</p> <p>vol. 65, no. 7, 1 April 2003 (2003-04-01), pages 1103-1113, XP001181103</p> <p>ISSN: 0006-2952</p> <p>the whole document</p> <p>-----</p>	9-12,19,20
Y	<p>WOOD M D ET AL: "The human GABAB1b and GABAB2 heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen"</p> <p>BRITISH JOURNAL OF PHARMACOLOGY,</p> <p>vol. 131, no. 6, November 2000 (2000-11), pages 1050-1054, XP001180958</p> <p>ISSN: 0007-1188</p> <p>the whole document</p> <p>-----</p>	1-24
X	<p>URWYLER STEPHAN ET AL: "Positive allosteric modulation of native and recombinant gamma-aminobutyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501"</p> <p>MOLECULAR PHARMACOLOGY,</p> <p>vol. 60, no. 5, November 2001 (2001-11), pages 963-971, XP001153169</p> <p>ISSN: 0026-895X</p> <p>the whole document</p> <p>-----</p>	9-12,19,20
Y	<p>DATABASE CA [Online]</p> <p>CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;</p> <p>NEMERYUK, M. P. ET AL: "Synthesis and pharmacological activity of 4,9-diamino derivatives of 7,8-dihydro-1,3-diazaphenothiazine"</p> <p>XP002318964</p> <p>retrieved from STN</p> <p>Database accession no. 1986:460576</p> <p>abstract</p> <p>-----</p>	1-24
X	<p>DATABASE CA [Online]</p> <p>CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;</p> <p>NEMERYUK, M. P. ET AL: "Synthesis and pharmacological activity of 4,9-diamino derivatives of 7,8-dihydro-1,3-diazaphenothiazine"</p> <p>XP002318964</p> <p>retrieved from STN</p> <p>Database accession no. 1986:460576</p> <p>abstract</p> <p>-----</p>	25

-/--



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/052029

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>&amp; KHIMIKO-FARMATSEVTICHESKII ZHURNAL , 19(8), 964-8 CODEN: KHFZAN; ISSN: 0023-1134, 1985,</p> <p>-----</p> <p>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NEMERYUK, M. P. ET AL: "4-Methoxy-7,8-dihydro-1,3-diazaphenthiazine ne amino derivatives and their neurotropic activity" XP002318965 retrieved from STN Database accession no. 1986:406472 abstract</p> <p>&amp; KHIMIKO-FARMATSEVTICHESKII ZHURNAL , 19(7), 810-14 CODEN: KHFZAN; ISSN: 0023-1134, 1985,</p>	25
X	<p>-----</p> <p>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; POLEZHAEVA, A. I. ET AL: "Derivatives of dihydropyrimido[4,5-b][1,4]benzothiazine and their pharmacological properties" XP002318966 retrieved from STN Database accession no. 1982:85508 abstract</p> <p>&amp; KHIMIKO-FARMATSEVTICHESKII ZHURNAL , 15(11), 45-50 CODEN: KHFZAN; ISSN: 0023-1134, 1981,</p>	25
A	<p>-----</p> <p>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TYURINA, L. A. ET AL: "Algorithmic search for folic acid antagonists among the derivatives of pyrimido[4,5-b](1,4)benzothiazine" XP002318967 retrieved from STN Database accession no. 1986:454098 abstract</p> <p>&amp; KHIMIKO-FARMATSEVTICHESKII ZHURNAL , 19(9), 1080-6 CODEN: KHFZAN; ISSN: 0023-1134, 1985,</p> <p>-----</p> <p style="text-align: center;">-/--</p>	25

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/052029

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199410 Derwent Publications Ltd., London, GB; Class B02, AN 1994-081438 XP002318968 -& SU 811 776 A1 (A MED RADIOLOGY RES INST) 15 November 1993 (1993-11-15) abstract -----	25
X	WO 98/11885 A (ASTRA AKTIEBOLAG; ANDREWS, PAUL, L., R; LEHMANN, ANDERS) 26 March 1998 (1998-03-26) the whole document -----	25-29